lncRNA CASC2与肿瘤化疗耐药实验研究进展

doi:10.11904/j.issn.1002-3070.2024.01.011

实用肿瘤学杂志 ›› 2024, Vol. 38 ›› Issue (1): 67-70.doi: 10.11904/j.issn.1002-3070.2024.01.011

• 综述 • 上一篇

lncRNA CASC2与肿瘤化疗耐药实验研究进展

尚宏悦, 姚曼曼, 路月亭, 王迪娴, 赵乾综述, 刘铁军审校

河北医科大学第四医院口腔科(石家庄 050011)

收稿日期:2023-10-15 修回日期:2024-01-26 出版日期:2024-02-28 发布日期:2024-06-21
通讯作者: 刘铁军,E-mail:47300561@hebmu.edu.cn
作者简介:尚宏悦,女,(1999-),硕士研究生,从事口腔肿瘤分子诊断与治疗的相关研究。

Research progress of long non-coding RNA CASC2 in tumor chemotherapy resistance

SHANG Hongyue, YAO Manman, LU Yueting, WANG Dixian, ZHAO Qian, LIU Tiejun

Department of Stomatology,the Fourth Hospital of Hebei Medical University,Shijiazhuang 050011,China

Received:2023-10-15 Revised:2024-01-26 Online:2024-02-28 Published:2024-06-21

摘要/Abstract

摘要： 恶性肿瘤目前已经成为导致人类死亡的主要疾病,随着治疗过程中化疗药物使用时效不断延长,肿瘤细胞耐药性也不断增强。长链非编码RNA(long non-coding RNA,lncRNA)是非编码RNA家族的重要成员,癌症易感候选物2(Cancer susceptibility candidate 2,CASC2)是一种长链非编码RNA,CASC2高表达可以抑制肿瘤细胞发展,并可以通过促进耐药细胞凋亡、调节信号通路、参与细胞传导途径、竞争性结合miRNA以及改变蛋白结构或功能状态等机制来降低肿瘤细胞的耐药性.本文将对lncRNA CASC2与恶性肿瘤化疗耐药调控作用及机制作一综述。

关键词: 长链非编码RNA, 癌症易感候选物2, 化疗, 耐药, 肿瘤

Abstract: Malignant tumors have become the main cause of human death.With the prolonged use of chemotherapeutic drugs during the treatment process,tumor cell resistance is also constantly increasing.long non-coding RNA(lncRNA)is an important member of the non-coding RNA family.Cancer susceptibility candidate 2(CASC2)is a type of long non-coding RNA,high expression of CASC2 can inhibit tumor cell development and reduce drug resistance of tumor cells by promoting apoptosis,regulating signaling pathways,participating in cellular transmission pathways,competitively binding of miRNA,and changing the protein structure or functional status.This article will provide a comprehensive review of the regulatory effects and mechanism of lncRNA CASC2 on chemotherapy resistance in malignant tumors.

Key words: long non-coding RNA, Cancer susceptibility candidate 2, Chemotherapy, Drug resistance, Tumor

中图分类号:

R730.53

尚宏悦, 姚曼曼, 路月亭, 王迪娴, 赵乾, 刘铁军. lncRNA CASC2与肿瘤化疗耐药实验研究进展[J]. 实用肿瘤学杂志, 2024, 38(1): 67-70.

SHANG Hongyue, YAO Manman, LU Yueting, WANG Dixian, ZHAO Qian, LIU Tiejun. Research progress of long non-coding RNA CASC2 in tumor chemotherapy resistance[J]. Journal of Practical Oncology, 2024, 38(1): 67-70.

参考文献

1 Sung H,Ferlay J,Siegel RL,et al.Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2021,71(3):209-249.
2 Hashemi M,Mirzaei S,Zandieh MA,et al.Long non-coding RNAs(lncRNAs)in hepatocellular carcinoma progression:Biological functions and new therapeutic targets[J].Prog Biophys Mol Biol,2023,177:207-228.
3 Zhou J,Song G,Su M,et al.Long noncoding RNA CASC9 promotes pancreatic cancer progression by acting as a ceRNA of miR-497-5p to upregulate expression of CCND1.[J].Environmental Toxicology,2023,38(6):1251-1264.
4 Lu P,Jiang Y,Xia Z.Long noncoding RNA TUG1 decreases bladder cancer chemo-sensitivity toward doxorubicin through elevating KPNA2 expression and activating the PI3K/AKT pathway via adsorbing miR-582-5p[J].Anticancer Drugs,2023,34(1):144-154.
5 杨钊,赵世光.长链非编码RNA CASC2抑制肿瘤发生发展的研究概况[J].实用肿瘤学杂志,2018,32(2):179-183.
6 Bao MH,Wong CC.Hypoxia,metabolic reprogramming,and drug resistance in liver cancer[J].Cells,2021,10(7):1715-1715.
7 栗敏,白桦,肖鹏,等.LncRNA GALNT5 uaRNA在TRAIL诱导的肺癌A549和HCC827细胞耐药中的作用[J].郑州大学学报(医学版),2022,57(6):745-751.
8 Jin X,Cai L,Wang C,et al.CASC2/miR-24/miR-221 modulates the TRAIL resistance of hepatocellular carcinoma cell through caspase-8/caspase-3[J].Cell Death Dis,2018,9(3):318.
9 Liu Z,Dang C,Xing E,et al.Overexpression of CASC2 improves cisplatin sensitivity in hepatocellular carcinoma through sponging miR-222[J].DNA Cell Biol,2019,38(11):1366-1373.
10 Sun J,Xu H,Lei Z,et al.The lncRNA CASC2 modulates hepatocellular carcinoma cell sensitivity and resistance to TRAIL through apoptotic and non-apoptotic signaling[J].Front Oncol,2021,11:726622.
11 Chen NP,Sun Z,Fässler R.The Kank family proteins in adhesion dynamics[J].Curr Opin Cell Biol,2018,54:130-136.
12 Wang J,Jia J,Zhou L.Long non-coding RNA CASC2 enhances cisplatin sensitivity in oral squamous cell cancer cells by the miR-31-5p/KANK1 axis[J].Neoplasma,2020,67(6):1279-1292.
13 Yang M,Luo Q,Chen X,et al.Bitter melon derived extracellular vesicles enhance the therapeutic effects and reduce the drug resistance of 5-fluorouracil on oral squamous cell carcinoma[J].J Nanobiotechnology,2021,19(1):259-259.
14 Pan L,Chen H,Bai Y,et al.Long non-coding RNA CASC2 serves as a ceRNA of microRNA-21 to promote PDCD4 expression in oral squamous cell carcinoma[J].Onco Targets Ther,2019,12:3377-3385.
15 Li Y,Lv S,Ning H,et al.Down-regulation of CASC2 contributes to cisplatin resistance in gastric cancer by sponging miR-19a[J].Biomed Pharmacother,2018,108:1775-1782.
16 Yang SM,Huang C,Li XF,et al.miR-21 confers cisplatin resistance in gastric cancer cells by regulating PTEN[J].Toxicology,2013,306:162-168.
17 Sun K,Zhang G.Long noncoding RNA CASC2 suppresses esophageal squamous cell carcinoma progression by increasing SOCS1 expression[J].Cell Bioscience,2019,9(1):90.
18 Ying J,Qiu X,Lu Y,et al.SOCS1 and its potential clinical role in tumor[J].Pathol Oncol Res.,2019,25(4):1295-1301.
19 Feng Y,Zou W,Hu C,et al.Modulation of CASC2/miR-21/PTEN pathway sensitizes cervical cancer to cisplatin[J].Arch Biochem Biophys,2017,623:20-30.
20 伍玲,杨勇波.LncRNA CASC2、miR-155-5p与上皮性卵巢癌病人化疗敏感性及预后的相关性研究[J].蚌埠医学院学报,2023,48(2):217-221.
21 Tao L,Tian P,Yang L,et al.LncRNA CASC2 enhances 131I sensitivity in papillary thyroid cancer by sponging miR-155[J].Biomed Res Int,2020,2020:7183629.
22 Gao W,Lin S,Cheng C,et al.Long non-coding RNA CASC2 regulates Sprouty2 via functioning as a competing endogenous RNA for miR-183 to modulate the sensitivity of prostate cancer cells to docetaxel[J].Arch Biochem Biophys,2019,665:69-78.
23 Samadaian N,Salehipour P,Ayati M,et al.A potential clinical significance of DAB2IP and SPRY2 transcript variants in prostate cancer.[J].Pathol Res Pract,2018,214(12):2018-2024.
24 Chiarini F,Evangelisti C,McCubrey JA,et al.Current treatment strategies for inhibiting mTOR in cancer[J].Trends Pharmacol Sci,2015,36(2):124-135.
25 Jiang C,Shen F,Du J,et al.Upregulation of CASC2 sensitized glioma to temozolomide cytotoxicity through autophagy inhibition by sponging miR-193a-5p and regulating mTOR expression[J].Biomed Pharmacother,2018,97:844-850.
26 Tan WL,Jain A,Takano A,et al.Novel therapeutic targets on the horizon for lung cancer[J].Lancet Oncol,2016,17(8):347-362.
27 Xiao XH,He SY.ELF1 activated long non-coding RNA CASC2 inhibits cisplatin resistance of non-small cell lung cancer via the miR-18a/IRF-2 signaling pathway[J].Eur Rev Med Pharmacol Sci,2020,24(6):3130-3142.
28 Zhang X,Dong N,Hu X.Wnt/β-catenin signaling inhibitors[J].Curr Top Med Chem,2023,23(10):880-896
29 刘红文,王贞,张启慧,等.lncRNA CASC2C靶向Wnt/β-catenin信号通路影响口腔鳞癌顺铂敏感性的实验研究[J].临床肿瘤学杂志,2020,25(10):876-881.
30 Al-Zahrani MH,Assidi M,Pushparaj PN,et al.Expression pattern,prognostic value and potential microRNA silencing of FZD8 in breast cancer[J].Oncol Lett,2023,26(5):477-477.
31 Majidinia M,Yousefi B.Long non-coding RNAs in cancer drug resistance development[J].DNA Repair(Amst),2016,45:25-33.

[1]	钟女娟, 马晶昱, 许志达. 2019年福建省福清市恶性肿瘤发病与死亡情况及2015—2019年趋势分析[J]. 实用肿瘤学杂志, 2024, 38(1): 1-6.
[2]	薄芸, 杭文璐, 左淑润, 董圆, 李海泉. 长链非编码RNA OTUD6B-AS1对肺腺癌A549细胞增殖、侵袭和迁移能力的影响[J]. 实用肿瘤学杂志, 2024, 38(1): 13-17.
[3]	郑鹏飞, 董良鹏, 高延鑫, 张一夫, 秦双. 白细胞介素-38对乳腺癌患者CD8⁺T淋巴细胞功能的影响[J]. 实用肿瘤学杂志, 2024, 38(1): 30-36.
[4]	谢俊岭. 活化白细胞黏附分子在乳腺癌中的研究进展[J]. 实用肿瘤学杂志, 2024, 38(1): 45-49.
[5]	高源, 唐钰涵, 王露, 赵文辉. 铜死亡在肿瘤中的研究进展[J]. 实用肿瘤学杂志, 2024, 38(1): 50-54.
[6]	肖鼎, 白俊丞, 张彬. 紫云英苷抗肿瘤作用相关信号通路的研究进展[J]. 实用肿瘤学杂志, 2024, 38(1): 62-66.
[7]	武春龙, 孙伟玲. 中国消化道肿瘤发病与死亡的年龄-时期-队列模型分析[J]. 实用肿瘤学杂志, 2023, 37(6): 459-465.
[8]	薛羽婷, 毛雄辉, 孙冀, 苑振楠. 长链非编码RNA LINC-PINT通过Hippo/YAP信号通路在缺氧诱导的头颈部鳞状细胞癌药物敏感性中的作用研究[J]. 实用肿瘤学杂志, 2023, 37(6): 466-471.
[9]	曹新玉, 周旭, 汪泉, 姜伟. 癌症药物耐药潜在机制及预测方法[J]. 实用肿瘤学杂志, 2023, 37(6): 491-495.
[10]	程锦, 王玮. 维甲酸诱导蛋白在消化系统恶性肿瘤中的研究进展[J]. 实用肿瘤学杂志, 2023, 37(6): 502-506.
[11]	赵世博, 陈永峰, 黎惠怡, 符爱珍. Agrin参与恶性肿瘤发生发展的研究现状[J]. 实用肿瘤学杂志, 2023, 37(6): 507-512.
[12]	宋述铭, 李改琴, 张黎峰, 许凯, 毛雯靖, 张光辉. 新疆医科大学附属肿瘤医院2010—2020年恶性肿瘤住院患者流行病学分析[J]. 实用肿瘤学杂志, 2023, 37(5): 389-394.
[13]	薛良方, 王欣舒, 张云艳, 成海燕, 靳红, 王耀先, 杨珊珊, 李奇. 尼妥珠单抗与贝伐珠单抗联合同步放化疗治疗局部晚期宫颈癌的疗效及不良反应对比研究[J]. 实用肿瘤学杂志, 2023, 37(5): 416-421.
[14]	刘远霖, 冯立. miR-192-5p在恶性肿瘤中作用机制的研究进展[J]. 实用肿瘤学杂志, 2023, 37(5): 439-442.
[15]	罗汀繁, 孙鹏飞. 巨噬细胞/小胶质细胞在胶质瘤微环境中的研究进展[J]. 实用肿瘤学杂志, 2023, 37(5): 443-448.

lncRNA CASC2与肿瘤化疗耐药实验研究进展

Research progress of long non-coding RNA CASC2 in tumor chemotherapy resistance

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价